Decursin and decursinol angelate inhibit VEGF-induced angiogenesis via suppression of the VEGFR-2-signaling pathway

Carcinogenesis

Volumn 30, Issue 4, 2009, Pages 655-661

  Jung, Myung Hwan ^a   Lee, Sun hee ^a   Ahn, Eun Mi ^b   Lee, You Mie ^a  

^a Kyungpook National University   (South Korea)

^b Daegu Haany University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ANGELICA GIGAS EXTRACT; DECURSIN; DECURSINOL ANGELATE; MITOGEN ACTIVATED PROTEIN KINASE; PYRANOCOUMARIN DERIVATIVE; STRESS ACTIVATED PROTEIN KINASE; TYROSINE KINASE RECEPTOR; UNCLASSIFIED DRUG; VASCULOTROPIN; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ARTICLE; CANCER INHIBITION; CELL MIGRATION; CELL PROLIFERATION; CHICK; CHORIOALLANTOIS; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ISOLATION; DRUG PURIFICATION; DRUG STRUCTURE; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; MICROVASCULATURE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; TIME TO MAXIMUM PLASMA CONCENTRATION; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR VOLUME; UMBILICAL VEIN;

ANIMALS; ANIMALS, GENETICALLY MODIFIED; APIACEAE; BENZOPYRANS; BLOTTING, WESTERN; BUTYRIC ACIDS; CARCINOMA, LEWIS LUNG; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; CHICKENS; CHORIOALLANTOIC MEMBRANE; EMBRYO, NONMAMMALIAN; ENDOTHELIUM, VASCULAR; HUMANS; IMMUNOENZYME TECHNIQUES; MICE; MICE, INBRED C57BL; NEOVASCULARIZATION, PATHOLOGIC; PLANT EXTRACTS; PROTEIN KINASE C; SIGNAL TRANSDUCTION; UMBILICAL VEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS; ZEBRAFISH;

EID: 64349105855     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp039     Document Type: Article

References (43)

1. Folkman,J. (1990) What is the evidence that tumors are angiogenesis dependent? J. Natl Cancer Inst., 82, 4-6.
2. Fidler,I.J. et al. (1994) The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell, 79, 185-188.
3. Hanahan,D. et al. (2000) The hallmarks of cancer. Cell, 100, 57-70.
4. Brem,S. et al. (1976) Prolonged tumor dormancy by prevention of neovascularization in the vitreous. Cancer Res., 36, 2807-2812.
5. Holmgren,L. et al. (1995) Dormancy of micrometastases: Balanced proliferation and apoptosis in the presence of angiogenesis suppression. Nat. Med., 1, 117-118.
6. Folkman,J. (1971) Tumor angiogenesis: Therapeutic implications. N. Engl. J. Med., 285, 1182-1186.
7. Shaheen,R.M. et al. (1999) Antiangiogenic therapy targeting the tyrosine kinase receptor for vascular endothelial growth factor receptor inhibits the growth of colon cancer liver metastasis and induces tumor and endothelial cell apoptosis. Cancer Res., 59, 5412-5416.
8. Kurebayashi,J. et al. (1999) Expression of vascular endothelial growth factor (VEGF) family members in breast cancer. Jpn. J. Cancer Res., 90, 977-981.
9. Yoshiji,H. et al. (1999) KDR/Flk-1 is a major regulator of vascular endothelial growth factor-induced tumor development and angiogenesis in murine hepatocellular carcinoma cells. Hepatology, 30, 1179-1186.
10. Droller,M.J. (1998) Vascular endothelial growth factor is a predictor of relapse and stage progression in superficial bladder cancer. J. Urol. 160, 1932.
11. Kitamura,M. et al. (1998) Concentrations of vascular endothelial growth factor in the sera of gastric cancer patients. Oncol. Rep., 5, 1419-1424.
12. Balbay,M.D. et al. (1999) Highly metastatic human prostate cancer growing within the prostate of athymic mice overexpresses vascular endothelial growth factor. Clin. Cancer Res., 5, 783-789.
13. McMahon,G. (2000) VEGF receptor signaling in tumor angiogenesis. Oncologist, 5, 3-10.
14. Chi,H.J. et al. (1970) Studies on the components of Umbelliferae plants in Korea: Pharmacological study of decursin, decursinol and nodakenin. Korean J. Pharmacol., 1, 25-32.
15. Lee,S. et al. (2003) Antitumor activity of decursinol angelate and decursin from Angelica gigas. Arch. Pharm. Res., 26, 727-730.
16. Lee,S. et al. (2002) Coumarins and pyrimidine from Angelica gigas roots. Nat. Prod. Sci., 8, 58-61.
17. Konoshima,M. et al. (1968) Coumarins from the root of Angelica gigas Nakai. Chem. Pharm. Bull., 16, 1139-1140.
18. Kang,S.Y. et al. (2003) Decursin from Angelica gigas mitigates amnesia induced by scopolamine in mice. Neurobiol. Learn. Mem., 79, 11-18.
19. Kim,D.H. et al. (2007) Nodakenin, a coumarin compound, ameliorates scopolamine-induced memory disruption in mice. Life Sci., 80 1944-1950.
20. Kim,H.H. et al. (2005) Involvement of PKC and ROS in the cytotoxic mechanism of anti-leukemic decursin and its derivatives and their structure-activity relationship in human K562 erythroleukemia and U937 myeloleukemia cells. Cancer Lett., 223, 191-201.
21. Lee,K.B. et al. (2008) Low energy proton beam induces tumor cell apoptosis through reactive oxygen species and activation of caspases. Exp. Mol. Med., 29, 118-129.
22. Westerfield,M. (1995) The Zebrafish Book. A Guide for the Laboratory Use of Zebrafish (Danio rerio), 3rd edn. University of Oregon Press, Eugene, OR3rd edn.
23. Yim,D.S. et al. (2005) A novel anticancer agent, decursin, induces G1 arrest and apoptosis in human prostate carcinoma cells. Cancer Res., 65, 1035-1043.
24. Kilic,E. et al. (2006) The phosphatidylinositol-3 kinase/Akt pathway mediates VEGF's neuroprotective activity and induces blood brain barrier permeability after focal cerebral ischemia. FASEB J., 20, 1185-1187.
25. Yao,J.S. et al. (2004) Minocycline exerts multiple inhibitory effects on vascular endothelial growth factor-induced smooth muscle cell migration: The role of ERK1/2, PI3K, and matrix metalloproteinases. Circ. Res., 95, 364-371.
26. Ferrara,N. (2005) The role of VEGF in the regulation of physiological and pathological angiogenesis. EXS, 94, 209-231.
27. Shibuya,M. (2001) Structure and function of VEGF/VEGF-receptor system involved in angiogenesis. Cell Struct. Funct., 26, 25-35.
28. Veikkola,T. et al. (1999) VEGFs, receptors and angiogenesis. Semin. Cancer Biol., 9, 211-220.
29. Paz,K. et al. (2005) Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective. Front. Biosci., 10, 1415-1439.
30. Zhu,Z. et al. (2002) Clinical development of angiogenesis inhibitors to vascular endothelial growth factor and its receptors as cancer therapeutics. Curr. Cancer Drug Targets, 2, 135-156.
31. Hicklin,D.J. et al. (2001) Monoclonal antibody strategies to block angiogenesis. Drug Discov. Today, 6, 517-528.
32. Meadows,K.N. et al. (2001) Vascular endothelial growth factor induction of the angiogenic phenotype require Ras activation. J. Biol. Chem., 276, 49289-49298.
33. Minet,E. et al. (2001) c-JUN gene induction and AP-1 activity is regulated by a JNK-dependent pathway in hypoxic HepG2 cells. Exp. Cell Res., 265, 114-124.
34. Hanemaaijer,R. et al. (2000) Increased gelatinase-A and gelatinase-B activities in malignant vs. benign breast tumors. Int. J. Cancer, 86, 204-207.
35. Xie,T.X. et al. (2006) Activation of stat3 in human melanoma promotes brain metastasis. Cancer Res., 66, 3188-3195.
36. Tanimura,S. et al. (2003) Specific blockade of the ERK pathway inhibits the invasiveness of tumor cells: Down-regulation of matrix metalloproteinase-3/-9/-14 and CD44. Biochem. Biophys. Res. Commun. 304, 801-806.
37. Lakka,S.S. et al. (2002) Downregulation of MMP-9 in ERK-mutated stable transfectants inhibits glioma invasion in vitro. Oncogene, 21, 5601-5608.
38. Kuo,L. et al. (2006) Src oncogene activates MMP-2 expression via the ERK/Sp1 pathway. J. Cell. Physiol., 207, 729-734.
39. Ferrara,N. et al. (2004) Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov., 3, 391-400.
40. Park,R.J. et al. (2001) Comparative studies on concentration of decursinol in plasma after oral administration of Angelicae gigantis radix extract and combined use of decursin and Cnidii rhizoma extract or Bupleuri radix extract in rats. Korean J. Pharmacogn., 32, 72-78.
41. Jiang,C. et al. (2007) Decursin and decursinol angelate inhibit estrogen-stimulated and estrogen-independent growth and survival of breast cancer cells. Breast Cancer Res., 9, R77.
42. Guo,J. et al. (2007) A novel class of pyranocoumarin anti-androgen receptor signaling compounds. Mol. Cancer Ther., 6, 907-917.
43. Jiang,C. et al. (2006) Potent antiandrogen and androgen receptor activities of an Angelica gigas-containing herbal formulation: identification of decursin as a novel and active compound with implications for prevention and treatment of prostate cancer. Cancer Res., 66, 453-463.